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This study demonstrates that methyl-CpG-binding PCR (MB-PCR) is a rapid and simple method for detecting fragile X syndrome
(FXS) in males, which is performed by verifying the methylation status of the FMR1 promoter in bloodspots. Proteins containing
methyl-CpG-binding (MB) domains can be freeze-stored and used as stocks, and the entire test requires only a few hours. The
minimum amount of DNA required for the test is 0.5ng. At this amount, detection sensitivity is not hampered, even mixing with
excess unmethylated alleles up to 320 folds. We examined bloodspots from 100 males, including 24 with FXS, in a blinded manner.
The results revealed that the ability of MB-PCR to detect FMR1 promoter methylation was the same as that of Southern blot
hybridization. Since individuals with 2 or more X chromosomes generally have methylated FMR1 alleles, MB-PCR cannot be used
to detect FXS in females.
Copyright © 2009 Ching-Cherng Tzeng et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Fragile X syndrome (FXS) is the most common form of
inherited mental retardation. This syndrome is caused by
mutations in the fragile X mental retardation-1 (FMR1)g e n e
(OMIM ∗309550); in most patients, this gene contains an
expanded CGG repeat in the 5 -untranslated region [1].
Alleles with a repeat number less than 59 do not expand
to full mutation upon a single transmission [2]. It was
initially thought that there are no phenotypic eﬀects in
individuals with repeats in the premutation range, that
is, between 59 and 200. However, the recent reports have
identiﬁed a degenerative disease caused by such repeats,
namely,fragileX-associatedtremor/ataxiasyndromeinolder
individuals and prematureovarian failurein women[3].The
premutation allele is unstable, and the repeat region tends
to expand while being transmitted to the next generation
via a carrier mother. Once there is a transition to full
mutation, that is, the FMR1 has a repeat region of more
than200CGGrepeats,therepeatregionandthesurrounding
CpG islands become hypermethylated, rendering the gene
transcriptionally inactive [1, 2].
To date, there is no curative treatment for this disease.
Nonetheless, establishment of a correct diagnosis of FXS can
not only reduce the stress and frustration of a parent at not
knowing the cause of a child’s developmental delay, but also
facilitate early intervention, thereby beneﬁting the patients
[4–6]. Due to its X-linked nature, FXS is predominantly
observed in males. It is rather diﬃcult to clinically diagnose
FXS in young boys because its phenotypic manifestations
are nonspeciﬁc and variable [7]. Therefore, some clinicians
prefer to use a simple molecular test to screen boys suspected
of having this disease. One of the frequently used tests is
based on polymerase chain reaction (PCR) ampliﬁcation
of the FMR1 CGG-repeat region. Moreover, because it is
relatively easy to collect and transport bloodspot samples
on ﬁlter paper, they are often used for molecular screening
purposes. If the PCR results are inconclusive, conﬁrmation2 Journal of Biomedicine and Biotechnology
tests need to be performed [7–9]. However, in such cases, it
is diﬃcult to verify whether the bloodspot samples contain
the methylated FMR1 promoter; this is mainly because of
the limited amount of DNA that can be isolated from
bloodspots.
Southern blot hybridization (SBH) is currently the
golden standard for conﬁrmation diagnosis of FXS. It can
not only detect/exclude the fully expanded repeats, but also
check the methylation status of the CGG repeats and the sur-
roundingCpGdinucleotidesintheFMR1gene.Methylation-
sensitive PCR is another commonly used method for ver-
ifying the aforementioned methylation status. However, in
addition to being extremely labor and time consuming, these
methods often require an amount of DNA more than what
can be obtained from bloodspot samples. Generally, more
than 1μg of high-molecular-weight DNA is required for
SBH. Methylation-sensitive PCR is a very speciﬁc method;
although the sensitivity of this method has been reported to
be as high as 1ng [10], many studies have reported the use
of more than 500ng of DNA for a reliable assessment [11–
14]. This is because the DNA sample is subject to signiﬁcant
degradationduring thebisulﬁteconversionprocess[15],and
additional sample loss occursduring the subsequentremoval
of the bisulﬁte and desulfonation steps [16].
Recently, 3 articles reported a novel assay for detecting
methylated sequences of interest in samples with 1ng or less
DNA[17–19].Polypeptidescontainingmethyl-CpG-binding
domains (MBDs) have been used in the abovementioned
studies to speciﬁcally retain methylated DNA sequences
in a solid matrix. The methylated sequence(s) of interest
could then be detected using a variety of techniques. We
thus developed a similar assay, namely, methyl-CpG-binding
PCR (MB-PCR) [18]. In this study, we ﬁrst determined the
optimal conditions for this assay for reliably distinguishing
between the control DNA samples with and without methy-
lated FMR1 promoters. Next, we tested the reliability of this
assay in a blinded manner by examining bloodspot samples
obtained from 100 males, including 24 with FXS.
2.MaterialsandMethods
2.1. Strategy and Samples. Universally methylated or
unmethylated genomic DNAs were used as positive and
negative methylation controls, respectively, to determine
the optimal conditions critical for the success of MB-PCR.
Universally methylated DNA was prepared by treating
lymphocyte DNA with M.SssI[ 20], while universally
unmethylated DNA was prepared using nested whole
genome ampliﬁcation of the same DNA sample with phi29
DNA polymerase [21]. Then, we applied the optimized MB-
PCR to examine the bloodspot samples from 100 males in a
blinded manner. These subjects had been well characterized
by SBH. Finally, comparing the SBH results, we estimated
the sensitivity, speciﬁcity, and accuracy of MB-PCR by
using the formula described at the following html address:
http://www.rapid-diagnostics.org/accuracy.htm. The Insti-
tutional Ethics Committee at Chi Mei Medical Center
approved this study (IRB09602-002).
Between 2002 and 2007, 1399 males submitted blood
samplestoourlaboratoryformolecularanalysisoftheFMR1
mutation. Of the 229 males who submitted 3mL of venous
blood for SBH, 10 were successfully diagnosed with FXS
(Table 1). The procedure of SBH used in this study has
beenpublishedelsewhere[22].Another1170subjectsmailed
bloodspot samples on a ﬁlter paper to our laboratory for
a free-of-charge screening PCR, in which the FMR1 CGG-
repeat region was ampliﬁed. The protocol of screening PCR
used in this study has been described elsewhere [9]. Most of
thesesamplesshowedastrongpositivePCRresult,indicating
that they were unlikely aﬀected with FXS. The ampliﬁcation
results of 30 samples were either weak (n = 16) or negative
(n = 14). These subjects were then encouraged to undergo
another free-of-charge SBH for conﬁrmation.
As indicated by markers in Table 1, from the 259 cases
that had been conﬁrmed by SBH, 100 cases were selected to
evaluate the reliability of the MB-PCR procedure described
below. The 100 samples screened included all the 24 FXS
cases, all the 16 non-FXS cases that had shown a weak or
negative PCR result, and another 60 non-FXS cases that were
randomly selected from the 219 cases that presented a strong
ampliﬁcation yield in the screening PCR. After eliminating
personal identiﬁers, the residual bloodspots from these 100
cases were randomly labeled and analyzed using MB-PCR in
a blinded manner.
2.2. Preparation of Recombinant MBD2b and MBD3L1
Polypeptides. The expression plasmids of glutathione-S-
transferase- (GST-) tagged MBD2b protein and histidine
(HIS-) tagged MBD3L1 protein were provided by Professor
GP Pfeifer [17]. After transforming Escherichia coli BL21
(DE3) with the plasmids, expression was induced with
1mM isopropylthio-β-galacoside (GIBCO BRL, Carlsbad,
CA, USA) for 3hours at 37◦C. Bacterial pellets were resus-
pended in ice-cold STE buﬀer (10mM Tris-HCl, pH 7.8,
150mM NaCl, and 1mM or 0.1mM EDTA for MBD2b
and MBD3L1, resp.) containing 1mM phenulmethylsulfonyl
ﬂuoride (GIBCO BRL, Carlsbad, CA, USA) and 200μL
Protease Inhibitor Cocktail Set II or VII (Calbiochem, Merck
KgaA, Darmstadt, Germany) for MBD2b and MBD3L1,
respectively. After incubating the cells for 10minutes on
ice, 0.3% of N-lauroylsarcosine (Sigma, St. Louis, MO,
USA) was added, and a pressure of 1000 atm was applied
through a French pressure cell press (Thermo Spectronic,
Madison, WI, USA) for bacterial lysis. The lysate was
cleared by centrifugation and loaded onto a GSTrap 4B
column (GE Healthcare, Uppsala, Sweden) or HiTrap chelat-
ing HP column (GE Healthcare, Uppsala, Sweden), as
appropriate. The columns and the tagged proteins were
washed extensively and eluted according to the manufac-
turer’s recommendations. The eluted proteins were dialyzed
against 2 L of PBS at 4◦C for 5hours, followed by
further overnight dialysis against storage buﬀer (50 mM
HEPES, pH 7.4, 150mM NaCl, 5mM 2-mercaptoethanol,
and 50% glycerol) at 4◦C. After dialysis, the proteins
were stored in aliquots at –20◦C; their activity was unaf-
fected for at least 6 months. The purity and concentra-
tions of the recombinant proteins were assessed by 12.5%Journal of Biomedicine and Biotechnology 3
Table 1: Molecular testing of 1399 males suspected of having fragile X syndrome.
Methylation (+) Methylation (–)
Screening PCR SBH MB-PCR SBH MB-PCR
Venous blood Strong 219§ 0 0 219 60
Weak 0
Failed 10∗ 10 10 0 0
Bloodspot Strong 1140
Weak # 16∗ 2 2 14 14
Failed # 14∗ 12 12 2 2
Total 1399 24 24 235 76
Methylation(+)andMethylation(–):presenceandabsenceofmethylatedFMR1promoter,respectively;SBH:Southernblothybridization;MB-PCR:methyl-
CpG-binding PCR; §: of which 60 cases were randomly selected for the blinded test; ∗: all cases included for the blinded test; #: SBH was performed using
resubmitted venous blood samples.
SDS-polyacrylamide gel electrophoresis and staining with
Coomassie blue, as shown in supplementary material avail-
able online at doi:10.1155/2009/643692.
2.3. Cleavage of Genomic DNA. The procedures used for
DNA isolation from venous blood and dried bloodspots
have been described elsewhere [9]. To determine the best
method for DNA cleavage, we compared the results of
restriction enzyme digestion of the same DNA samples
withMseI(T/TAA),MspI(C/CGG),ormethylation-sensitive
BstUI (C/GCG) (New England BioLabs, Beverly, MA, USA),
individually or in combination. The relative locations of the
recognition sites of these enzymes and MB-PCR primers are
shown in Figure 1. It has been reported that the cytosines in
the 14 CpG dinucleotides between the MspI recognition sites
are methylated in FXS males and unmethylated in non-FXS
males [23, 24].
2.4. Methyl-CpG-binding PCR. Figure 2 shows a simple
ﬂow diagram of MB-PCR. A day before the MB-PCR
procedure was performed, 50μL of recombinant MBD2b
protein (15μg/mL in 10mM Tris-HCl (pH 7.5)) was applied
to the wells of the heat-stable TopYield Strip (Nunc,
Roskilde, Denmark) and incubated at 4◦C overnight [18].
The polycarbonate TopYield Strip has a high-binding aﬃnity
for proteins. After washing 3 times with 200μLo fT B S
(20mM Tris (pH 7.5) and 170mM NaCl), each well with the
recombinant protein was incubated with 100μL of blocking
solution (10mM Tris (pH 7.5), 170mM NaCl, 5% skim milk
p o w d e r ,5 m ME D T A ,a n d1 μg/mL of each poly (dI-dC),
poly (dA-dT), and poly (dC-dG) (Amersham, Piscataway,
NJ, USA)) at 4◦C for 2 h. Each well was then washed twice
with 200μL of TBST (20mM Tris (pH 7.5), 170 mM NaCl,
and 0.05% Tween-20) and then with the binding buﬀer
[20mM Tris (pH 7.5), 2 mM MgCl2,0 . 5m ME D T A ,0 . 0 5 %
Tween-20,andNaClatdiﬀerentconcentrationsrangingfrom
100mM to 700mM]. A total of 20μL of predigested DNA
was mixed with 50μL of binding solution and 13μLo f
recombinant MBD3L1 protein solution (60μg/mL in 10mM
Tris-HCl(pH7.5))andloadedontothewells.Aftera1-hours
incubation on a shaker (250rpm) at room temperature, the
wells were washed twice with 200μL of binding buﬀer and
once with 200μL of 10mM Tris-HCl (pH 8.0) to remove the
unmethylated fragments.
In each batch of MB-PCR assay, either universally
methylated or unmethylated DNA samples were included as
positive or negative control, respectively. Each sample was
routinely examined twice in the same batch of MB-PCR.
One received the whole stringency washes as above. The
other did not receive the washes because the cleaved DNA
samples were added last and therefore escaped the stringent
washing steps [18]. Subsequently, these wells were subjected
toPCRampliﬁcationbyadding30μLofPCRmixture,which
contained 72.5mM Tris HCl (pH 9.0), 20mM (NH4)2SO4,
1.5mM MgCl2, 0.01% (w/v) Tween-20, 200nM dNTP,
2.5% glycerol, 200nM of both primers (Figure 1), and
0.75 U Super-Therm DNA polymerase (Laboratory Product
International, Kent, UK). The reaction conditions were as
follows: initial denaturation at 95◦C for 5minutes; 36, 40, or
45 cycles at 95◦Cf o r1m i n u t e s ;5 9 ◦Cf o r1m i n u t e s ;7 2 ◦C
for 45 seconds a ﬁnal extension at 72◦Cf o r1 0m i n u t e s .
Subsequently, ampliﬁed products were resolved on a 5%
polyacrylamide gel and visualized with ethidium bromide
stain and UV illumination.
3. Results
3.1. Speciﬁcity of MB-PCR. The most important step in this
experiment was to determine the optimal NaCl concentra-
tion of the binding buﬀer; this is critical for enhancing the
speciﬁcityoftheMBDcomplextodistinctly bindwith FMR1
alleles with diﬀerent methylation statuses. We used 2.5ng of
theuniversallymethylatedorunmethylatedDNAsamplesfor
the optimization experiments. After MspIo rMseI digestion,
each cleaved DNA sample was added to a binding buﬀer
that contains diﬀerent concentrations of NaCl ranging from
1 0 0m Mt o7 0 0m M ;i tw a st h e nl o a d e di na nM B D - c o a t e d
PCR well.
The results of PCR ampliﬁcation are shown in
Figure 3(a). Where no stringency washes were performed,
thePCRproductsofallsamplesdigestedbythesameenzyme
showed similar intensities. The MspI-digested samples
exhibit slightly stronger intensity of the ampliﬁcation
products than MseI-digested ones. Where stringency washes4 Journal of Biomedicine and Biotechnology
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Figure 1: (a) Relative locations of recognition sites of restriction enzymes MseI, MspI, and BstUI and MB-PCR primers. (b) Sequence of
FMR1 promoter region. The methylated cytosine of CpG dinucleotides is indicated by an enlarged letter “C”; the recognition sites of MspI
and BstUI are double underlined; the primers are indicated by arrows.
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Figure 2: Flow diagram of methyl-CpG-binding PCR.
were performed, the PCR products of all the universally
unmethylated samples were not discernible, except in the
case of a week yield in an MseI-digested sample for which a
low-stringency wash with 100mM NaCl was performed. On
the contrary, the PCR products of many of the universally
methylated samples showed variable intensities. In general,
the intensity of PCR products decreases gradually with an
increase in NaCl concentration in the stringency wash. The
optimal NaCl concentrations in the stringency washes that
helped in reliably distinguishing between methylated and
unmethylated samples ranged from 100nM to 500nM in the
case of the MspI-digested samples. However, the range for
the MseI-digested samples narrowed down to 200–300nM.
Next, we examined the results of using a methylation-
sensitive enzyme (BstUI) alone and in combination with
MspIo rMseI. Addition of BstUI can remove most of
the unmethylated alleles in test samples, thus reducing the
chances of false-positive results in MB-PCR [19]. How-
ever, when BstUI alone is used, no discernible PCR yield
was observed (Figure 3(b), top panel). These results are
consistent with the MB-PCR results shown in Figure 3(a),
suggesting that the BstUI-digested fragments were most
likely too long to be easily trapped by the MBD complex
under such washing conditions. On the other hand, PCR
using DNA cleaved with MseIo rMspI yielded rather speciﬁc
results,regardlessofwhetherBstUIdigestionwasperformed.
Importantly, the sensitivity of PCR with MspI digestion was
higher than that with MseI digestion.
3.2. Sensitivity of MB-PCR. As expected, when DNA was
cleaved using MspI alone, the detection sensitivity of methy-
latedFMR1promoterintheFXSsamplesimprovedgradually
with increasing number of MB-PCR cycles (Figure 4(a)).
Moreover, the NaCl concentrations in the stringency washes
also aﬀect the detection sensitivity. The results revealed that
the minimum amount of DNA required for unequivocal
detection of speciﬁc products in 45 cycles of MB-PCR
ampliﬁcationis 0.5ngand1.0ngwhenstringencywashesare
performed with 300mM and 400mM NaCl, respectively.
Next, we evaluated if the optimized MB-PCR can reliably
detect males with the mosaic form of FXS who often
have expanded FMR1 alleles in either the methylated or
unmethylated states. We thus simulated such mosaic samples
by mixing 0.5ng of the DNA from an FXS male havingJournal of Biomedicine and Biotechnology 5
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Figure 3: Factors critical for the detection speciﬁcity of MB-PCR.
(a) NaCl concentration in the stringency wash and enzymatic
cleavage of the test DNA are the major factors that can critically
determine the capability of MB-PCR in distinguishing between
sampleswithmethylatedandunmethylatedFMR1alleles.(b)Under
the same MB-PCR condition, including a stringency wash with
400mM NaCl and 45 PCR cycles of ampliﬁcation, the samples
cleaved by diﬀerent restriction enzyme(s) varied considerably in the
detection sensitivity. (–) Control DNA with universally unmethy-
lated sequences; (+): control DNA with universally methylated
sequences; (M): molecular-size markers
a nonmosaic methylation pattern with diﬀerent amounts of
DNA from a non-FXS male, ranging from 2.5ng to 160ng.
Using the optimized MB-PCR conditions, including an NaCl
concentration of 300mM in the binding buﬀer, digestion
of DNA with MspI, and 45 cycles of PCR ampliﬁcation,
we found that the methylated FMR1 promoter could be
detected in mosaic samples, even when the amount of non-
FXS sample was 160ng (Figure 4(b)).
3.3. Reliability of MB-PCR. Before the blinded screening of
the 100 bloodspot samples, we ﬁrst performed MB-PCR on
6 representative samples, which were from 4 non-FXS males
and 2 FXS males. The corresponding results of the screening
PCR and SBH for these 6 samples are shown in Figures
5(a) and 5(b), respectively. The MB-PCR analysis of the 6
300mM
400mM
Cycle
numbers
40
45
40
45
M1 0
(−)( + )
5.0 H2O1 0 2 .0 1.0 0.5 0.25 ng
DNA of FXS male
200 bp
100 bp
(a)
M1 0
(−)( + )
1.0 160 160 80 40 20 10 5.0 2.5 ng
D N Ao fn o n - F X Sm a l e
200 bp
100 bp
00 .5 0.5 0.5 0.5 0.5 0.5 0.5 ng
D N Ao fF X Sm a l e
(b)
Figure 4: Detection sensitivity of MB-PCR. (a) MB-PCR analysis
using diﬀerent amounts of input DNA, cycle numbers of the PCR
ampliﬁcation,andNaClconcentrationinthestringencywashes.(b)
MB-PCR analysis of the DNA samples simulated as mosaic FXS
by mixing 0.5ng of DNA sample from an FXS male with varying
amounts of DNA sample from a non-FXS male. (–): Control DNA
with universally unmethylated sequences; (+): control DNA with
universally methylated sequences; (M): molecular-size markers.
representative cases yielded a positive result only for 2 FXS
samples (Figure 5(c)).
Next, we applied the optimized MB-PCR to examine
the residual bloodspot samples from the aforementioned
100 males, including 24 with FXS, in a blinded manner. A
total of 5μL of DNA sample from each case—approximately
0.5–12ng DNA—was used for the test. The results are
summarized in Table 1. Compared with the SBH results,
the MB-PCR could detect all 24 FXS males, with 100%
sensitivity, speciﬁcity, and accuracy.
4. Discussion
MBD polypeptides are the core elements of this MB-PCR
assay and other similar methods. The family of vertebrate
MBD proteins comprises MeCP2, MBD1, MBD2, MBD3,
and MBD4 [25, 26]. MeCP2 was the ﬁrst protein applied
to an aﬃnity matrix to speciﬁcally retain the sequences that
are highly methylated [27]. However, since the use of MeCP2
requires A/T-rich sequences adjacent to the methylated CpG
dinucleotides for eﬃcient DNA binding, all methods based6 Journal of Biomedicine and Biotechnology
390 bp
348 bp
315 bp
194 bp
(CGG)n
98
54
40
29
IL1B
(a)
5.2K b
2.8K b
(CGG)n
122
54
29
Methylated
full
mutation
(b)
Stringency wash
M1 23 456M
No
Yes
200 bp
100 bp
(c)
Figure 5: Representative males examined with (a) screening PCR,
(b)Southernblothybridization,and(c)methyl-CpG-bindingPCR.
For the non-FXS samples, the CGG repeat numbers are 29 (lanes
1 and 6), 54 (lane 2), and 98 (lane 3). For the FXS samples, lane
4 is a mosaic pattern comprising expanded FMR1 alleles with and
withoutmethylation,andunmethylatedalleleswithCGG-repeatsin
thenormalrange(indicated byarrows),andlane5hasanonmosaic
pattern. (M): molecular size markers.
on MeCP2 aﬃnity might be biased towards certain CpG
motifs [28]. The main MBD protein used in this study was
MBD2b, because MBD2 exhibits a higher aﬃnity for CpG-
methylated DNA than other MBD proteins [29]. MBD2b is
theisoformofMBD2athatlackstheN-terminalregionofthe
152 amino acids proximal to the MBD [28]. MBD3L1 itself
lacks the ability to bind methylated DNA but can interact
with MBD2b and enhance its binding aﬃnity for methylated
sequences [29]. Because the MBD3L1-interaction domain
hasbeenmappedtotheC-terminalendofMBD2b,theentire
MBD2b protein (29.1kD) should be used in MB-PCR [17],
instead of the truncated MBD domain (7kD) used in the
other related studies [18, 19].
Other factors critically determining the sensitivity and
speciﬁcity of this assay are the NaCl concentration of the
binding buﬀer and the method used for DNA cleavage.
The former must be determined by performing a series of
titration tests. In this study, we found that the best optimal
NaCl concentration of the binding buﬀer was between
300 and 400mM. The optimal NaCl concentration values
reported in 3 other similar studies analyzing diﬀerent targets
ranged from 700mM [17] and 400mM [18]t o5 0 m M
[19]. DNA cleavage has often been performed by sonication
or restriction enzyme digestion. The former appears to be
ineﬀective in samples with limited amount of DNA; hence,
we compared the results of the MB-PCR assay by using 3
restrictionenzymesaloneorincombinationwithothers.The
results of this comparison experiment reveal that, for groups
of samples with diminished amounts of DNA, the MspI-
based group provides consistently stronger product signals
than the group based on MseI digestion. When DNA is
cleaved using MseIo rMspI digestion, the FMR1 fragments
that cover the primers used in this study are 1633bp and
141bp long, respectively (Figure 1). It seems likely that the
longer DNA fragments are more easily removed from the
MBD complex during subsequent washing steps.
Under the conditions optimized previously, the MB-
PCR could reliably distinguish DNA samples of the FXS
group from those of the non-FXS group. However, this
assay cannot be used to detect FXS in females, because the
FMR1 allele in the inactivated X chromosome(s) of females
is mostly methylated. In-house preparation of MBD proteins
makes the test more cost eﬀective, provided that the requisite
facilities are available. The proteins can be freeze-stored and
used as stocks, and the entire test can be completed within a
few hours. Notably, the minimum amount of DNA required
for the test is only 0.5ng, which can be easily obtained
from a bloodspot sample. Even when mixing 0.5ng of DNA
fromanFXSmalewitha320-fold-concentratedDNAsample
(160ng) from a non-FXS male, the detection sensitivity and
speciﬁcity of MB-PCR remains unchanged. On the basis of
the results of an FXS case (Figure 5, lane 4), it is plausible to
believe that this assay is reliable in detecting FXS males with
mosaicmethylationpatterns,whoaccountforapproximately
12–41% of male FXS patients [30, 31]. Interestingly, these
results also suggest that the reliability of MB-PCR is retained
when it is used to screen DNA samples pooled from many
male subjects.
As demonstrated in this study, MB-PCR is a simple and
aﬀordable test to rapidly elucidate the methylation status of
the FMR1 promoter in the bloodspots. This test would be
particularly useful for the samples that show a negative or
decreasedPCRsignalduringinitialscreening.Thebloodspot
samples that showed negative results in the PCR screening
test (e.g., lane 5, Figure 5) were often conﬁrmed to be FXS-
positive by using either SBH or MB-PCR (Table 1). Negative
PCR results are also possibly observed in samples carrying
a large-sized premutation in or deletion of a related FMR1
region, although such cases were not observed in our study.
Decreased PCR signals may be attributed to the presence of
am o s a i cf o r mo fF X So rt oam e d i u m - s i z e dp r e m u t a t i o n
or simply to an artifact of the sample DNA. Taking intoJournal of Biomedicine and Biotechnology 7
consideration the cases we have conﬁrmed with SBH, we
ﬁnd that the interpretational uncertainty of these cases could
be greatly reduced, when the IL1B gene is included as a
comparative PCR control for the evaluation of the quantity
and quality of bloodspot DNA. Those samples that exhibit
decreased PCR yield intensity for FMR1 but not for IL1B,
like that in lane 4, are often conﬁrmed to be FXS-positive. If
the subjects carry a medium-sized premutation allele (e.g.,
lane 3, Figure 5), the PCR products of FMR1 often have
a decreased intensity but increased size; the corresponding
ampliﬁcation intensity of IL1B is often strong. On the other
hand, the cases exhibiting similar decrease in yields for
both FMR1 and IL1B,( e . g . ,l a n e6 ,Figure 5)a r eo f t e nF X S -
negative.
According to the Best Practice Guidelines for Molecular
Analysis in Fragile X Syndrome provided by The European
MolecularGeneticsQualityNetwork(http://www.emqn.org/
emqn/), the golden standard of the diagnosis of the FXS
is SBH, which detects not only methylation but also
methylation mosaics, expansions of the FMR1 CGG repeat,
and deletions of the FMR1 promoter. Compared with the
SBH results, we demonstrated that the MB-PCR could
detect all 24 FXS males in the blind examination of 100
bloodspot samples, with 100% sensitivity, speciﬁcity, and
accuracy. Similar detection power has been reported in
methylation-sensitive PCR using methylated FMR1 alleles
[11–14]. However, this method could not be easily applied
to the bloodspot samples. Further, SBH cannot be used to
analyze samples with DNA at a nanogram level thus far.
Hence, in combination with screening PCR, MB-PCR can
accelerate and simplify the detection of FXS in males. In the
case of negative results in both tests, the subjects may have a
large-sizedpremutationordeletionofarelatedFMR1region.
For the case of the former condition, many studies have used
diﬀerent PCR methods to verify the expanded CGG repeats
[32–36].
In conclusion, we demonstrated for the ﬁrst time that the
MB-PCR is a simple and inexpensive test and can accelerate
and simplify the detection of FXS in males by rapidly
verifying the FMR1 promoter methylation in bloodspots. In-
house preparation of MBD proteins makes the test more
cost-eﬀective. The freeze-stored proteins can be used as
stocks, and the entire test can be completed within a
few hours. Under the optimized conditions, the minimum
amount of DNA required for the test is only 0.5ng, and the
detection sensitivity is not hampered at this concentration
even after mixing it with a 320-fold-concentrated sample
containing unmethylated alleles (160ng). Since individuals
with 2 or more X chromosomes generally have methylated
FMR1 alleles, MB-PCR cannot be used to detect FXS in
females.
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